安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- PROVENGE (sipuleucel-T) | FDA
Indication: For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer
- DailyMed - PROVENGE- sipuleucel-t injection
PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
- Provenge (sipuleucel-T)
This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine OncoHealth reserves the right to request medical documentation as needed to validate medical necessity determinations
- Sipuleucel-t Monograph for Professionals - Drugs. com
It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity
- PROVENGE 5. 6 Product Safety Testing - PROVENGE (sipuleucel-T)
PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
- Sipuleucel-T - NCI - National Cancer Institute
FDA label information for this drug is available at DailyMed Sipuleucel-T is approved to treat: Prostate cancer that has metastasized (spread to other parts of the body) It is used in men who have few or no symptoms and whose cancer is hormone-refractory (does not respond to hormone treatment)
- Provenge® (sipuleucel-T) - OHSU
Referenced with permission from the NCCN Drugs Biologics Compendium (NCCN Compendium®) for Sipuleucel-T National Comprehensive Cancer Network, 2025 The NCCN Compendium® is a derivative work of the NCCN Guidelines®
- Provenge (sipuleucel-T) - CVS Caremark
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy
|
|
|